Urokinase in experimental vitreous hemorrhage.
Toxicity of intravitreal urokinase was studied by injection of various doses of urokinase in primate eyes. Doses of 22,500 CTA units or less produced no toxic effects on the eye. Higher doses caused retinal degeneration, transient lens opacities, and cloudy vitreous. Urokinase was ineffective in clearing experimentally induced vitreous hemorrhage if injected as early as 24 hours after the intravitreal blood or as late as six months thereafter.
D000818:Animals; D002386:Cataract / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D010450:Endopeptidases / Q000627:therapeutic use*; D005128:Eye Diseases / Q000188:drug therapy; D000882:Haplorhini; D006470:Hemorrhage / Q000188:drug therapy*; D010786:Photoreceptor Cells / Q000473:pathology; D012164:Retinal Diseases / Q000139:chemically induced / Q000473:pathology; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D014822:Vitreous Body / Q000187:drug effects
D010450:Endopeptidases; D014568:Urokinase-Type Plasminogen Activator